Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 227287

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 227287

License Grant
The Irish Licensor hereby grants to the UK Licensee the following exclusive option (the Option), during the Option Period, to obtain an exclusive transfer and assignment of the Rights, on the terms stated and incorporated by this reference, to use, promote, distribute and sell the Product in the Territory, for use in the field of human therapeutic treatment of any disease, condition or disorder (the Field). It is understood and agreed that Licensor retains all rights in the Product outside the Territory which it now or hereafter may own or control.
License Property
The Product is relating to a Zydis® formulation of selegeline hydrochloride presently known as Zelapar™, which may have utility in the treatment of Parkinson’s disease and other diseases or conditions.
Field of Use
Licensee has US marketing rights for Zelapar (Zydis fast-dissolving formulation of selegiline), a late-stage product in development also for treatment of Parkinson's disease.

IPSCIO Record ID: 126

License Grant
The Licencor hereby grants to Licensee an exclusive option, to obtain an exclusive transfer and assignment of the Rights, on the terms stated below, to use, promote, distribute and sell the Product in the Territory,   It is understood and agreed that the Licensor retains all rights in the Product outside the Territory which it now or hereafter may own or control.
License Property
The agreements relates to a Zydis® formulation of selegeline hydrochloride presently known as Zelapar™. Zelapar is added to levodopa/carbidopa treatment of Parkinson’s disease in patients who are experiencing a reduced response to this therapy. Zelapar is a fast melt formulation of selegiline for the treatment of Parkinson’s disease.
Field of Use
The Option rights are for use in the field of human therapeutic treatment of any disease, condition or disorder.

IPSCIO Record ID: 4453

License Grant
In 2001, Licensor had entered into a distribution and option agreement with the third party, whereby the third party agreed to market and distribute Permaxtm (pergolide mesylate) in the United States.  

In February 2004, the Licensor, further amended their contractual arrangements subject to the sale by a third party (original Licensee)of certain of its assets, including its rights to Zelapar and Permax, to the (current)Licensee. On 25 February 2004, third party’s sale of assets to Licensee closed and the amendments became effective.

License Property
Permax is used for the treatment of Parkinson’s disease and Zelapar is a fast melt formulation of selegiline for the treatment of Parkinson’s disease.  Permax has been approved for marketing in the US as an adjunctive treatment for Parkinson’s disease, a neurological disease characterized by a deficiency of dopamine, a neurotransmitter, in the brain. Permax is one of a class of drugs known as dopamine agonists, which mimic the action of dopamine at certain receptor sites in the brain. Stimulating these receptor sites can reduce the symptoms of Parkinson’s disease, such as tremor, rigidity and shuffling gait. Other competing pharmaceutical products, including dopamine agonists and products having different mechanisms of action, have also been approved for treatment of the symptoms of Parkinson’s disease.
Field of Use
The rights granted apply to the drug market relating to the pharmaceutical healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.